SYMPOSIUM 2: Prospective implementation of pharmacogenomics in clinical practice: NGS versus targeted genotyping strategies
Tracks
Track 2
| Monday, September 22, 2025 |
| 11:00 AM - 12:30 PM |
| Grand Copthorne Waterfront Hotel - Waterfront Ballroom I |
Details
To date, targeted genotyping strategies remain the cornerstone of clinical pharmacogenetics. However, next-generation sequencing technologies (NGS) have developed rapidly and are becoming increasingly attractive as an alternative strategy. The application of advanced sequencing technologies can overcome the problems associated with rarer and more population-specific variants than commonly used targeted pharmacogenetic panels. On the other hand, technical feasibility and challenges related to cost and data management may limit the transferability of these approaches into clinical practice. In this symposium challenges will be outlined and solutions presented and discussed in the context of implementation examples from clinical practice showcasing research and implementation from the Asia-Pacific region.
Speaker
Prof Rachel Conyers
Cancer Therapies Group, Murdoch Children's Research Institute
Minimising Adverse Drug Reactions and Verifying Economic Legitimacy Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation
Biography
Prof Yusuke Tanigawara
Laboratory of Pharmacometrics and Systems Pharmacology, K-FRECS at Tonomachi, Keio University
Clinical implementation of next generation sequencing derived 18-gene pharmacogenomic panel for personalized drug therapy in a general hospital
Biography
Prof Andrew Somogyi
University Of Adelaide
Integration of pharmacokinetic, pharmacogenetic and pharmacodynamic data in cancer pain management – the example of oxycodone
Biography
Andrew Somogyi graduated in Pharmacy from Tasmania and completed a PhD from the University of Sydney (Pharmacy-Anaesthetics). He then undertook postdoctoral clinical pharmacology training in Bonn (Germany) under the guidance of Michel Eichelbaum, and for the past 40 years has been at the University of Adelaide. Apart from teaching in medical, dental, health sciences, nursing and physiotherapy courses, he has an active research programme examining interindividual variation in drug response through clinical pharmacokinetic, pharmacodynamic and outcomes studies underpinned by pharmacogenomics. His current research covers the fields of acute postoperative and cancer pain and psychiatry with a specific focus on ketamine and opioids and, HIV therapy in Papua New Guinea. He is a contributing member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and an honorary fellow of the Faculty of Pain Medicine (FFPMANZCA), a Fellow of the British Pharmacological Society and an ASCEPT Fellow.
Prof Jae-Gook Shin
Pharmacogenomics Research Center at Inje University College of Medicine, Busan
The Center for Personalized Precision Medicine of Tuberculosis (cPMTb) to develop personalized pharmacotherapeutic systems for tuberculosis (TB) integrating genomic data
Biography
Session chair
Erika Cecchin
Centro Di Riferimento Oncologico Di Aviano
Jesse Swen
Leiden University Medical Center
